Healthcare provider profile · identity verified

William Sandoval, MD

Family Practice · BELVIDERE, IL · NPI 1912080912

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	720	266
Metformin Hcl	Metformin Hcl	340	115
Amlodipine Besylate	Amlodipine Besylate	262	91
Lisinopril	Lisinopril	257	85
Losartan Potassium	Losartan Potassium	236	82
Metformin Hcl Er	Metformin Hcl	194	74
Tamsulosin Hcl	Tamsulosin Hcl	189	78
Levothyroxine Sodium	Levothyroxine Sodium	151	52
Metoprolol Succinate	Metoprolol Succinate	114	36
Jardiance	Empagliflozin	112	42
Simvastatin	Simvastatin	98	31
Hydrochlorothiazide	Hydrochlorothiazide	92	36
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	91	36
Enalapril Maleate	Enalapril Maleate	83	24
Glipizide	Glipizide	80	28
Gabapentin	Gabapentin	78	45
Carvedilol	Carvedilol	77	27
Rosuvastatin Calcium	Rosuvastatin Calcium	73	27
Glimepiride	Glimepiride	66	23
Tradjenta	Linagliptin	64	15
Pravastatin Sodium	Pravastatin Sodium	57	22
Escitalopram Oxalate	Escitalopram Oxalate	56	26
Januvia	Sitagliptin Phosphate	55	16
Fluticasone Propionate	Fluticasone Propionate	54	31
Alendronate Sodium	Alendronate Sodium	53	21
Omeprazole	Omeprazole	53	27
Glipizide Er	Glipizide	52	12
Pantoprazole Sodium	Pantoprazole Sodium	51	34
Allopurinol	Allopurinol	48	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	48	19
Metoprolol Tartrate	Metoprolol Tartrate	47	19
Nifedipine Er	Nifedipine	44	14
Duloxetine Hcl	Duloxetine Hcl	43	16
Meloxicam	Meloxicam	43	29
Albuterol Sulfate Hfa	Albuterol Sulfate	39	19
Montelukast Sodium	Montelukast Sodium	38	20
Famotidine	Famotidine	33	11
Farxiga	Dapagliflozin Propanediol	33	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	31	12
Ozempic	Semaglutide	30	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	27	suppressed
Citalopram Hbr	Citalopram Hydrobromide	24	11
Mirtazapine	Mirtazapine	24	15
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	24	12
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Furosemide	Furosemide	23	12
Lovastatin	Lovastatin	23	suppressed
Levemir Flexpen	Insulin Detemir	21	11
Sildenafil Citrate	Sildenafil Citrate	21	suppressed
Eliquis	Apixaban	20	suppressed
Clopidogrel	Clopidogrel Bisulfate	18	suppressed
Ketoconazole	Ketoconazole	18	13
Sertraline Hcl	Sertraline Hcl	18	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	18	suppressed
Vascepa	Icosapent Ethyl	18	suppressed
Ezetimibe	Ezetimibe	17	suppressed
Trazodone Hcl	Trazodone Hcl	17	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	16	suppressed
Trulicity	Dulaglutide	16	suppressed
Chlorthalidone	Chlorthalidone	15	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Hydralazine Hcl	Hydralazine Hcl	15	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	15	suppressed
Myrbetriq	Mirabegron	14	suppressed
Rybelsus	Semaglutide	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Trueplus Pen Needle	Pen Needle, Diabetic	14	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Benazepril Hcl	Benazepril Hcl	12	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Single Use Swab	Alcohol Antiseptic Pads	12	suppressed
Valsartan	Valsartan	12	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	11	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	suppressed
Irbesartan	Irbesartan	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error